ARS Pharmaceuticals Says Express Scripts Has Added Neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies
ARS Pharmaceuticals Announces Neffy (Epinephrine Nasal Spray) Is Available on Express Scripts Commercial National Formularies
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ARS Pharmaceuticals Files For Approval Of Neffy In China, Japan And Australia
ARS Pharmaceuticals | 10-Q/A: Quarterly report (Amendment)
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
ARS Pharmaceuticals Announces Planned Launch of NeffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
Trade Alert: Chief Business Officer & Secretary Of ARS Pharmaceuticals Justin Chakma Has Sold Stock
Form 144 | ARS Pharmaceuticals(SPRY.US) Officer Proposes to Sell 4.09 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 15, $ARS Pharmaceuticals(SPRY.US)$ Officer Chakma Justin intends to sell 236.38K shares of its common stock on Nov 15, with a total market value of approximately $4.09
Express News | Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing
Express News | ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $26 From $25
ARS Pharmaceuticals' Strong Q3 2024 Highlights
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$10.14 Million in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Flynn James E sold 563.27K shares of common stock on Nov 11, 12, 2024 at an average price of $18.01 for a total value of $10.14 million. This
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript Summary
ARS Pharmaceuticals Shares Are Higher Lower After the Company Reported Better-than-expected Q3 Sales Results.
ARS Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
ARS Pharmaceuticals | 8-K: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
ARS Pharmaceuticals' Q3 Net Loss Widens
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates